Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43227   clinical trials with a EudraCT protocol, of which   7153   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2017-000891-27
    Sponsor's Protocol Code Number:CLNP023X2203
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2019-08-12
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2017-000891-27
    A.3Full title of the trial
    An adaptive seamless randomized, double-blind, placebo-controlled, dose ranging study to investigate the efficacy and safety of LNP023 in primary IgA nephropathy patients
    Etude de recherche de dose adaptative, combinée, randomisée, en double aveugle, contrôlée versus placebo, destinée à évaluer l'efficacité et la sécurité d’emploi du LNP023 chez des patients atteints de néphropathie primaire à IgA
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Study of safety and efficacy of LNP023 in patients with a kidney disorder called IgAN nephropathy
    A.4.1Sponsor's protocol code numberCLNP023X2203
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorNovartis Pharma AG
    B.1.3.4CountrySwitzerland
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportNovartis Pharma AG
    B.4.2CountrySwitzerland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationNovartis Pharma S.A.S
    B.5.2Functional name of contact pointInformation&Communication Médicales
    B.5.3 Address:
    B.5.3.1Street Address8/10 rue Henry Sainte Claire Deville, CS 40150
    B.5.3.2Town/ cityRueil-Malmaison
    B.5.3.3Post code92563
    B.5.3.4CountryFrance
    B.5.4Telephone number+33 1 5547 6600
    B.5.5Fax number+33 1 5547 6100
    B.5.6E-mailicm.phfr@novartis.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code LNP023
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNnot yet established
    D.3.9.3Other descriptive name LNP023 HYDROCHLORIDE SALT
    D.3.9.4EV Substance CodeSUB180361
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code LNP023
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNnot yet established
    D.3.9.3Other descriptive name LNP023 HYDROCHLORIDE SALT
    D.3.9.4EV Substance CodeSUB180361
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code LNP023
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNnot yet established
    D.3.9.3Other descriptive name LNP023 HYDROCHLORIDE SALT
    D.3.9.4EV Substance CodeSUB180361
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCapsule, hard
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Primary IgA Nephropathy
    Néphropathie primaire à IgA
    E.1.1.1Medical condition in easily understood language
    Kidney disorder
    Maladie rénale
    E.1.1.2Therapeutic area Diseases [C] - Immune System Diseases [C20]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level HLGT
    E.1.2Classification code 10029149
    E.1.2Term Nephropathies
    E.1.2System Organ Class 10038359 - Renal and urinary disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the dose response relationship of LNP023 on the reduction in proteinuria versus placebo after 90 days of treatment in patients with IgA nephropathy.
    Evaluer la relation dose-réponse de LNP023 sur la réduction de la protéinurie par rapport au placebo après 90 jours de traitement chez les patients atteints de néphropathie IgA.
    E.2.2Secondary objectives of the trial
    -To evaluate the safety and tolerability of LNP023
    -To assess the effect of LNP023 on renal function up to 90 days of
    treatment (combining Part 1 and Part2 of the study)
    -To assess the pharmacokinetics of LNP023
    -To assess the effect of LNP023 on alternative complement pathway
    -To estimate the lowest dose that provides maximal reduction of proteinuria
    - To assess the effect of LNP023 on renal function up to Day 180 (Part 2 of the study)
    - Evaluer les profils de sécurité d’emploi et de tolérance du LNP023
    - Evaluer l'effet du LNP023 sur la fonction rénale pendant une durée maximale de 90 jours de traitement (en combinant la Partie 1 et la Partie 2 de l'étude)
    - Evaluer la pharmacocinétique du LNP023
    - Evaluer l'effet du LNP023 sur la voie alterne d'activation du complément
    - Estimer la dose la plus faible entraînant une réduction maximale de la protéinurie
    - Evaluer l'effet du LNP023 sur la fonction rénale jusqu'au jour 180 (Partie 2 de l'étude)
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    • Female and male patients ≥18 years of age with a biopsy-verified IgA nephropathy and where the biopsy was performed within the previous three years. If the most recent renal biopsy was performed more than three years ago, a new biopsy should be performed.
    • Patients must weigh at least 35 kg to participate in the study, and must have a body mass index (BMI) within the range of 15 - 38 kg/m2. BMI =Body weight (kg) / [Height (m)]2
    •Measured Glomerular Filtration Rate (GFR) or estimated GFR calculated using the CKD-EPI formula (or modified MDRD formula according to specific ethnic groups and local practice guidelines [Imai, et al, 2011]) ≥30 mL/min per 1.73 m2
    • UPCR ≥0.8 g/g (≥90 mg/mmol) sampled from first morning void (FMV) or urine protein ≥0.75 g/24hr from a 24h urine collection at screening and urine protein ≥0.75 g / 24h from a 24h urine collection at the completion of the run- in period
    • Vaccination against Neisseria meningitidis types A, C, Y and W-135 is required at least 4 weeks prior to first dosing with LNP023. Vaccination against N. meningitidis type B, S. pneumoniae and H. influenzae should be conducted if available and acceptable by local regulations, at least 4 weeks prior to first dosing with LNP023
    • All patients must have been on supportive care including a maximally tolerated dose of ACEi or ARB therapy for the individual, antihypertensive therapy or diuretics for at least 90 days before dosing.

    Other protocol defined inclusion criteria may apply.
    • Femmes et hommes ≥ 18 ans présentant une néphropathie à IgA vérifiée par biopsie et si la biopsie a été réalisée au cours des trois années précédentes. Si la biopsie rénale la plus récente a été réalisée il y a plus de trois ans, une nouvelle biopsie doit être réalisée.
    • Avoir un poids d’au moins 35 kg pour participer à l'étude et un indice de masse corporelle (IMC) dans la plage de 15 à 38 kg/m2. IMC = poids corporel (kg)/[Taille (m)]2
    • DFG mesuré ou DFG estimé calculé à l'aide de la formule CKD-EPI (ou de la formule MDRD modifiée en fonction des groupes ethniques spécifiques et des directives relatives aux pratique locales (Imai et al 2011) ≥ 30 ml/min/1,73 m2
    • Rapport protéine/créatinine urinaire (RPCU) ≥ 0,8 g/g (≥ 90 mg/mmol) à partir d’un échantillon des premières urines du matin (FMV) ou protéines dans les urines ≥ 0,75 g/24 h à partir d’un recueil des urines sur 24 heures à la sélection et protéine urinaire ≥ 0,75 g/24 h à partir d’un recueil des urines sur 24 heures à la fin de la période de pré-inclusion
    • Vaccination obligatoire contre Neisseria meningitidis de types A, C, Y et W-135 au moins 4 semaines avant la première administration de LNP023. Une vaccination contre N. meningitidis de type B doit être réalisée, si elle est disponible et acceptable par les réglementations locales, au moins 4 semaines avant l’administration de la première dose
    • Tous les patients doivent avoir reçu des soins de soutien, y compris une dose maximale tolérée d’IECA ou d’ARA en tant que traitement antihypertenseur individuel ou des diurétiques pendant au moins 90 jours avant l’administration de la dose

    D'autres critères d'inclusion définis dans le protocole peuvent s'appliquer.
    E.4Principal exclusion criteria
    • Presence of crescent formation in ≥50% of glomeruli assessed on renal biopsy
    • Patients previously treated with immunosuppressive agents such as cyclophosphamide, mycophenolate mofetil (MMF) or mycophenolate sodium, cyclosporine, tacrolimus, sirolimus, or systemic corticosteroids within 90 days prior to start of LNP023/Placebo dosing
    • All transplanted patients (any organ, including bone marrow)
    • History of immunodeficiency diseases, or a positive Human
    Immunodeficiency Virus (HIV; ELISA and Western blot) test result.
    • Chronic infection with Hepatitis B (HBV) or Hepatitis C (HCV). A positive HBV surface antigen (HBsAg) test, or if standard local practice, a positive HBV core antigen test, excludes a patient. Patients with a positive HCV antibody test should have HCV RNA levels measured. Subjects with positive (detectable) HCV RNA should be excluded
    • Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the subject in case of participation in the study. The Investigator should make this determination in consideration of the subject’s medical history and/or clinical or laboratory evidence of any of the following:
    •  A history of invasive infections caused by encapsulated organisms e.g. meningococcus or pneumococcus
     • Splenectomy
     • Inflammatory bowel disease, peptic ulcers, severe gastrointestinal disorder including rectal bleeding;
    • Major gastrointestinal tract surgery such as gastrectomy,
    gastroenterostomy, or bowel resection;
     • Pancreatic injury or pancreatitis;
     • Liver disease or liver injury as indicated by abnormal liver function tests. ALT (SGPT), AST (SGOT), GGT, alkaline phosphatase and
    serum bilirubin will be tested.
     • Any single parameter of ALT, AST, GGT, alkaline phosphatase or serum bilirubin must not exceed 3 x upper limit of normal (ULN)
     • Prothrombin Time / International normalized ration (PT/INR) must be within the reference range of normal individuals
    Evidence of urinary obstruction or difficulty in voiding any urinary tract
    disorder other than IgAN that is associated with hematuria at
    screening; [If necessary, laboratory testing may be repeated on one
    occasion (as soon as possible) prior to randomization, to rule out any
    laboratory error]
    • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test.
    • A history of clinically significant electrocardiogram (ECG)abnormalities, or any of the following ECG abnormalities at screening or baseline:
     • PR > 200 msec
     • QRS complex > 120 msec
    • QTcF > 450 msec (males)
     • QTcF > 460 msec (females)
    • History of familial long QT syndrome or known family history of Torsades de Pointes
    • Use of agents known to prolong the QT interval unless they can be
    permanently discontinued for the duration of the study
    • History of severe allergic reactions as per Investigator decision
    • Female patients who are pregnant or breastfeeding, or intending to conceive during the course of the study
    • Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception from first dosing with LNP023 until an additional one week following cessation of study drug. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in-situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases
    • History of any porphyria metabolic disorder

    Other protocol defined exclusion criteria may apply
    • Présence de formations en croissant dans ≥ 50% des glomérules d’après biopsie rénale
    • Traitement antérieur avec des agents immunosuppresseurs tels que cyclophosphamide, mycophénolate de mofétil (MMF) ou mycophénolate de sodium, cyclosporine, tacrolimus, sirolimus ou avec une corticothérapie systémique dans les 90 jours précédant le début de l’administration du LNP023/Placebo
    • Toutes les greffes (tout organe, y compris la moelle osseuse)
    • Antécédents de pathologies immunodéficitaires, ou résultat positif au dépistage du VIH (ELISA ou Western blot).
    • Infection chronique par le virus de l'hépatite B (VHB) ou de l'hépatite C (VHC). Un test de recherche de l’antigène de surface du VHB (AgHBs) positif, ou le cas échéant conformément à la pratique clinique locale, un test d'antigène de la nucléocapside du VHB positif, exclut toute participation à l’étude du patient. Si le test de recherche d'anticorps anti-VHC est positif, le taux d'ARN du VHC doit être déterminé. Les patients pour lesquels l’ARN du VHC est positif (détectable) doivent être exclus
    • Toute affection chirurgicale ou médicale susceptible de modifier significativement l’absorption, la distribution, le métabolisme ou l’excrétion des médicaments, ou pouvant mettre le patient en danger en cas de participation à l’étude. Pour cette évaluation, l’investigateur doit prendre en considération les antécédents du patient et/ou les données probantes cliniques ou biologiques de l'un des paramètres suivants :
    - Antécédents d'infections invasives provoquées par des organismes encapsulés, par exemple, méningocoque ou pneumocoque
    - Splénectomie
    - Maladie inflammatoire de l’intestin, ulcères peptiques, affections gastro-intestinales sévères, y compris saignement rectal;
    - Interventions chirurgicales majeures du tractus gastro-intestinal, telle qu’une gastrectomie, gastro-entérostomie ou résection intestinale;
    - Lésion pancréatique ou pancréatite;
    - Pathologie hépatique ou lésion hépatique, indiquée par des résultats anormaux des explorations fonctionnelles hépatiques. Les paramètres mesurés sont les suivants : ALAT (SGPT), ASAT (SGOT), γ-GT, phosphatase alcaline et bilirubine sérique
    - Chaque paramètre unique, à savoir ALAT, ASAT, γ-GT, phosphatase alcaline ou bilirubine sérique, ne doit pas dépasser 3 x la limite supérieure de la normale (LSN)
    - La valeur de PT/INR doit être dans la plage de référence des individus normaux
    - Preuve de la présence d’une obstruction urinaire ou de difficultés de miction, tout trouble des voies urinaires autre qu'une néphropathie à IgA associé à une hématurie lors de la sélection et avant l’administration de la dose ; [Si nécessaire, les analyses biologiques peuvent être répétées une fois (le plus tôt possible) avant la randomisation afin d'exclure toute erreur d'analyse.]
    • Grossesse ou allaitement au sein, la grossesse étant définie comme l'état de la femme après la conception et jusqu'au terme de la gestation, confirmée par un dosage biologique positif d'hCG
    • Antécédents d’anomalies ECG cliniquement significatives ou l'une des anomalies ECG suivantes à la sélection ou à l'inclusion :
    - PR > 200 msec
    - Complexe QRS > 120 msec.
    - QTcF > 450 ms (hommes)
    - QTcF > 460 ms (femmes)
    - Antécédents de syndrome du QT long congénital ou antécédents familiaux connus de torsades de pointes.
    - Utilisation d'agents connus pour entraîner un allongement de l'intervalle QT, sauf s'il est possible de les arrêter définitivement pendant toute la durée de l'étude.
    • Antécédents de réactions allergiques sévères conformément à la décision de l'investigateur
    • Femmes enceinte ou allaitantes ou ayant l'intention de devenir enceinte au cours de l'étude
    • Femmes en âge de procréer, à savoir toute femme physiologiquement apte à être enceinte, sauf si elles utilisent des méthodes de contraception efficaces à compter de l’administration de la première dose et pendant 1 semaine supplémentaire après l'arrêt du médicament de l’étude
    • Antécédents de tumeur maligne de tout système d'organes (hormis le carcinome basocellulaire cutané localisé ou le cancer du col utérin in-situ) au cours des 5 dernières années, que ce soit avec ou sans signe de récidive locale ou de métastases
    • Antécédents de tout trouble métabolique de type porphyrie

    D'autres critères d'exclusion définis dans le protocole peuvent s'appliquer.
    E.5 End points
    E.5.1Primary end point(s)
    The primary variable for the statistical analysis is the ratio to baseline of urine protein to creatinine concentration ratio (UPCR based on 24h urine collection) at 90 days
    Le critère d’évaluation principal pour les analyses statistiques est le ratio par rapport aux valeurs initiales (baseline) du rapport protéinurie/créatininurie (RPCU) mesuré à 90 jours (RPCU basé sur un recueil d'urines des 24 h).
    E.5.1.1Timepoint(s) of evaluation of this end point
    Baseline and day 90
    Valeurs initiales (baseline) et jour 90
    E.5.2Secondary end point(s)
    - Assessment of safety based on vital signs, physical examination, ECGs, laboratory assessments, and collection of AEs assessed from baseline until the end of the study visit
    - Estimated glomerular filtration rate (eGFR; estimated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation);
    Serum creatinine ;Hematuria (number of erythrocytes/high-power-field (hpf) measured through microscopic examination); 24h-UP, 24h-UA, UACR (urine albumin to creatinine concentration ratio); UPCR (urine protein to creatinine concentration ratio) from first morning void.
    - Plasma: Non-compartmental parameters related to total parent drug, including but not limited to Tmax, Cmax, AUClast and AUCtau will be calculated for each dose level; Urine: Non-compartmental parameters, including but not limited to total cumulative urinary excretion (Ae) and renal plasma clearance (CLr)
    - Plasma levels of alternative pathway biomarkers including Bb and sC5b-9
    - Ratio to baseline of UPCR
    - Estimated glomerular filtration rate (eGFR; estimated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation)
    UPCR from 24 hour sample and first morning void Hematuria (number of erythrocytes/high-power-field (hpf) measured through microscopic examination) UACR (urine albumin to creatinine concentration ratio).

    - Evaluation de la sécurité d’emploi d’après les signes vitaux, l'examen clinique, les ECG, les évaluations biologiques et le recueil des EI de la baseline jusqu'à la visite de fin d'étude
    - Débit de filtration glomérulaire estimé (DFGe ; estimé à l'aide de l'équation CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
    Créatinine sérique; hématurie (nombre d'érythrocytes/champ haute puissance (hpf) mesuré par un examen microscopique); 24h-PU, 24h-AU, RACU (rapport albuminurie/créatininurie); RPCU (rapport protéinurie/créatininurie) sur les premières urines du matin.
    - Plasma : Les paramètres non compartimentaux liés au médicament parent total, y compris sans toutefois s'y limiter, Tmax, Cmax, ASC dernière et ASC tau seront calculés pour chaque niveau de dose
    - Taux plasmatiques des biomarqueurs de la voie alterne du complément, y compris Bb et sC5b-9.
    - Rapport RPCU à la baseline
    - Débit de filtration glomérulaire estimé (DFGe ; estimé à l'aide de l'équation CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration))
    RPCU sur un échantillon des urines recueillies sur 24 heures et sur les premières urines du matin; Hématurie (nombre d'érythrocytes/champ haute puissance (hpf) mesuré par un examen microscopique); RACU (rapport albuminurie/créatininurie).
    E.5.2.1Timepoint(s) of evaluation of this end point
    - Baseline, Day 1, 8, 15, 30, 90, 120
    - Baseline, Day 1, 8, 15, 30, 90, 120
    - Baseline, Day 1, 8, 15, 30, 60, 90, 120, 180
    - Baseline, Day 1, 30, 60, 90, 120, 180

    - Baseline, Day 1, 8, 15, 30, 60, 90

    - Baseline, Day 1, 8, 15, 30, 60, 90

    - Baseline, Day 1, 8, 15, 30, 60, 90

    - Baseline, Day 1, 8, 15, 30, 60, 90

    - Baseline, Day 1, 8, 15, 30, 60, 90
    - Valeurs initiales (baseline), Jours 1, 8, 15, 30, 90, 120
    - Valeurs initiales (baseline), Jours 1, 8, 15, 30, 90, 120
    - Valeurs initiales (baseline), Jous 1, 8, 15, 30, 60, 90, 120, 180
    - Valeurs initiales (baseline), Jours 1, 30, 60, 90, 120, 180

    - Valeurs initiales (baseline), Jours 1, 8, 15, 30, 60, 90

    - Valeurs initiales (baseline), Jours 1, 8, 15, 30, 60, 90

    - Valeurs initiales (baseline), Jours 1, 8, 15, 30, 60, 90

    - Valeurs initiales (baseline), Jours 1, 8, 15, 30, 60, 90

    - Valeurs initiales (baseline), Jours 1, 8, 15, 30, 60, 90
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    -Tolerability
    -effect of LNP023 on alternative complement pathway
    - Tolérance
    - Evaluer l'effet du LNP023 sur la voie alterne d'activation du complément
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    adaptive
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial5
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA37
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Australia
    Belgium
    Brazil
    Canada
    China
    Colombia
    Czech Republic
    Denmark
    Finland
    France
    Germany
    Hong Kong
    Hungary
    India
    Israel
    Italy
    Japan
    Korea, Republic of
    Lebanon
    Malaysia
    Netherlands
    Norway
    Philippines
    Singapore
    Spain
    Sweden
    Taiwan
    Thailand
    Turkey
    United Kingdom
    United States
    Jordan
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days27
    E.8.9.2In all countries concerned by the trial months20
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 99
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 1
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state3
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 62
    F.4.2.2In the whole clinical trial 100
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    After treatment, a safety follow up period of 90 days is implemented
    G. Investigator Networks to be involved in the Trial
    G.4 Investigator Network to be involved in the Trial: 1
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2019-10-11
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2019-10-29
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2021-06-22
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2023 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA